Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.
1 report, 1 independent
Updated Aug 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- GSK built a joint venture with Pfizer and subsequently distributed a stake in that venture to shareholders.
- Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.
- Pfizer is jointly marketing the drug Eliquis.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.